Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
HLX-3902 in Metastatic Solid Tumor: NCT07533708 Clinical Landscape Report 2026
15 October 2026
NCT07533708 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Pancreatic Mucinous-Cystic Neoplasm: NCT07529483 Clinical Landscape Report 2026
15 October 2026
NCT07529483 clinical landscape for Pancreatic Mucinous-Cystic Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Ezetimibe in Chronic kidney disease, Stage V: NCT07524101 Clinical Landscape Report 2026
15 October 2026
NCT07524101 clinical landscape for Chronic kidney disease, Stage V: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TL-003 in Colitis, Ulcerative: NCT07526519 Clinical Landscape Report 2026
15 October 2026
NCT07526519 clinical landscape for Colitis, Ulcerative: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in stomach adenocarcinoma: NCT07529613 Clinical Landscape Report 2026
15 October 2026
NCT07529613 clinical landscape for stomach adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AZD-8359 in Metastatic Prostate Carcinoma: NCT07529717 Clinical Landscape Report 2026
15 October 2026
NCT07529717 clinical landscape for Metastatic Prostate Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Canagliflozin Hemihydrate in Chronic Kidney Diseases: NCT07527390 Clinical Landscape Report 2026
15 October 2026
NCT07527390 clinical landscape for Chronic Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenvatinib mesylate in Advanced Hepatocellular Carcinoma: NCT07537985 Clinical Landscape Report 2026
15 October 2026
NCT07537985 clinical landscape for Advanced Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Sintilimab in Hepatocellular Carcinoma: NCT07537972 Clinical Landscape Report 2026
15 October 2026
NCT07537972 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Liver metastases: NCT07537946 Clinical Landscape Report 2026
15 October 2026
NCT07537946 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Finerenone in Diabetes Mellitus, Type 2: NCT07537088 Clinical Landscape Report 2026
15 October 2026
NCT07537088 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
3D-1015 in Metastatic castration-resistant prostate cancer: NCT07537010 Clinical Landscape Report 2026
15 October 2026
NCT07537010 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…